Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29581892 | 1.00 | GABRA1 (0.41) | GABRA1GABRB2TAAR1IDO1CYP1A2 | |
| SCHEMBL6275225 | 0.82 | GABRA1 (0.57) | GABRA1GABRB2TAAR1IDO1 | |
| SCHEMBL16956748 | 0.79 | GABRA1 (0.39) | GABRA1GABRB2TAAR1IDO1CYP1A2 | |
| SCHEMBL31051639 | 0.79 | GABRA1 (0.39) | GABRA1GABRB2TAAR1IDO1CYP1A2 | |
| SCHEMBL19443780 | 0.79 | GABRA1 (0.50) | GABRA1GABRB2TAAR1IDO1 | |
| SCHEMBL560812 | 0.77 | — | — | |
| SCHEMBL29506108 | 0.77 | — | — | |
| SCHEMBL3871871 | 0.76 | TAAR1 (0.37) | GABRA1GABRB2TAAR1IDO1 | |
| SCHEMBL31057408 | 0.76 | TAAR1 (0.37) | GABRA1GABRB2TAAR1IDO1 | |
| SCHEMBL19585380 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112876411-A | Compound and application thereof in synthesis of PDL1 antagonist drug molecules | 杭州阿诺生物医药科技有限公司 | 2021-06-01 | — | — | CN | claimed |
| US-20250144253-A1 | 3-((3-([1,1'-BIPHENYL]-3-YLMETHOXY)PHENOXY)METHYL)BENZONITRILE DERIVATIVES AND THE USE THEREOF | HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF E.V. (DE) | 2025-05-08 | — | — | US | disclosed |
| EP-4444423-A1 | 3-((3-([1,1'-BIPHENYL]-3-YLMETHOXY)PHENOXY)METHYL)BENZONITRILE DERIVATIVES AND THE USE THEREOF | Helmholtz-Zentrum Dresden - Rossendorf e.V. (DE) | 2024-10-16 | — | — | EP | disclosed |
| CN-118715214-A | 3- ((3- ([ 1,1' -Biphenyl ] -3-ylmethoxy) -phenoxy) methyl) benzonitrile derivative and application thereof | 赫姆霍兹-森德拉姆德雷斯顿-罗森多夫研究中心 | 2024-09-27 | — | — | CN | disclosed |
| CN-112313220-B | PD-L1 antagonist compounds | 厦门宝太生物科技股份有限公司 | 2023-11-03 | — | — | CN | disclosed |
| CN-116730940-A | Heterocyclic substituted biphenyl compound and medical application thereof | 中国药科大学 | 2023-09-12 | — | — | CN | disclosed |
| WO-2023104744-A1 | 3-((3-([1,1'-BIPHENYL]-3-YLMETHOXY)PHENOXY)METHYL)BENZONITRILE DERIVATIVES AND THE USE THEREOF | HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF E.V. (DE) | 2023-06-15 | — | — | WO | disclosed |
| EP-3450423-B1 | BENZYL PHENYL ETHER DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USES THEREOF | INST MATERIA MEDICA CAMS (CN) | 2022-06-15 | — | — | EP | disclosed |
| EP-3929188-A1 | PD-L1 ANTAGONIST COMPOUND | Adlai Nortye Biopharma Co., Ltd. (CN) | 2021-12-29 | — | — | EP | disclosed |
| CN-112876411-A | Compound and application thereof in synthesis of PDL1 antagonist drug molecules | 杭州阿诺生物医药科技有限公司 | 2021-06-01 | — | — | CN | disclosed |
| WO-2021043116-A1 | BIPHENYL COMPOUNDS, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 中国药科大学 | 2021-03-11 | — | — | WO | disclosed |
| CN-112313220-A | PD-L1 antagonist compounds | 杭州阿诺生物医药科技有限公司 | 2021-02-02 | — | — | CN | disclosed |
| WO-2017202273-A1 | BENZYL PHENYL ETHER DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USES THEREOF | 中国医学科学院药物研究所 | 2017-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250144253-A1 | 3-((3-([1,1'-BIPHENYL]-3-YLMETHOXY)PHENOXY)METHYL)BENZONITRILE DERIVATIVES AND THE USE THEREOF | CYP4B1, UGT2B7, UGT1A4 | GABRA1 498/4885GABRB2 238/4885TAAR1 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.